Protagonist Therapeutics Inc
PTGX85.400USD
+1.200+1.43%
終値 11/21, 16:00（ET）15分遅れの株価
5.29B時価総額
10.01直近12ヶ月PER
詳細情報 Protagonist Therapeutics Inc 企業名
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Protagonist Therapeutics Incの企業情報
企業コードPTGX
会社名Protagonist Therapeutics Inc
上場日Aug 11, 2016
最高経営責任者「CEO」Dr. Dinesh V. Patel, Ph.D.
従業員数126
証券種類Ordinary Share
決算期末Aug 11
本社所在地7707 Gateway Blvd Ste 140
都市NEWARK
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94560-1160
電話番号15104740170
ウェブサイトhttps://www.protagonist-inc.com/
企業コードPTGX
上場日Aug 11, 2016
最高経営責任者「CEO」Dr. Dinesh V. Patel, Ph.D.
Protagonist Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Wed, Nov 19
更新時刻: Wed, Nov 19
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
他の
56.19%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
他の
56.19%
種類
株主統計
比率
Investment Advisor
38.79%
Investment Advisor/Hedge Fund
35.88%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
8.46M
13.6%
-140.21K
-1.63%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.17M
9.92%
+65.00K
+1.06%
Jun 30, 2025
RTW Investments L.P.
5.76M
9.25%
+36.86K
+0.64%
Jun 30, 2025
The Vanguard Group, Inc.
4.35M
6.99%
+80.38K
+1.88%
Jun 30, 2025
State Street Investment Management (US)
3.21M
5.16%
+500.92K
+18.51%
Jun 30, 2025
BVF Partners L.P.
3.21M
5.16%
+636.03K
+24.70%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.94%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.04M
1.67%
+50.37K
+5.10%
Jun 30, 2025
UBS Financial Services, Inc.
2.50M
4.02%
+2.15M
+619.02%
Jun 30, 2025
Deep Track Capital LP
3.25M
5.22%
-4.10K
-0.13%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Invesco S&P SmallCap Health Care ETF
2.47%
ALPS Medical Breakthroughs ETF
2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
2.13%
ETC 6 Meridian Small Cap Equity ETF
1.29%
SPDR S&P Biotech ETF
1.28%
Cambria Value and Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Invesco S&P SmallCap Momentum ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.67%
詳細を見る
Invesco S&P SmallCap Health Care ETF
比率2.47%
ALPS Medical Breakthroughs ETF
比率2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
比率2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
比率2.13%
ETC 6 Meridian Small Cap Equity ETF
比率1.29%
SPDR S&P Biotech ETF
比率1.28%
Cambria Value and Momentum ETF
比率1%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.85%
Invesco S&P SmallCap Momentum ETF
比率0.77%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.67%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Protagonist Therapeutics Incの上位5名の株主は誰ですか？
Protagonist Therapeutics Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は8.46M株を保有しており、これは全体の13.60%に相当します。
Farallon Capital Management, L.L.C.は6.17M株を保有しており、これは全体の9.92%に相当します。
RTW Investments L.P.は5.76M株を保有しており、これは全体の9.25%に相当します。
The Vanguard Group, Inc.は4.35M株を保有しており、これは全体の6.99%に相当します。
State Street Investment Management (US)は3.21M株を保有しており、これは全体の5.16%に相当します。
BlackRock Institutional Trust Company, N.A.は8.46M株を保有しており、これは全体の13.60%に相当します。
Farallon Capital Management, L.L.C.は6.17M株を保有しており、これは全体の9.92%に相当します。
RTW Investments L.P.は5.76M株を保有しており、これは全体の9.25%に相当します。
The Vanguard Group, Inc.は4.35M株を保有しており、これは全体の6.99%に相当します。
State Street Investment Management (US)は3.21M株を保有しており、これは全体の5.16%に相当します。
Protagonist Therapeutics Incの株主タイプ上位3種は何ですか？
Protagonist Therapeutics Incの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
Protagonist Therapeutics Inc（PTGX）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Protagonist Therapeutics Incの株式を保有している機関は551社あり、保有株式の総市場価値は約71.95Mで、全体の115.09%を占めています。2025Q2と比較して、機関の持ち株は5.78%増加しています。
Protagonist Therapeutics Incの最大の収益源は何ですか？
--において、--部門がProtagonist Therapeutics Incにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
